The addition of macrolides for empiric treatment of patients hospitalized with moderate and high-severity community-acquired pneumonia (CAP) was not associated with improved clinical outcomes, according to a population-level study published this week in the Journal of Infectious Diseases.
Using electronic medical record data from 8,872 adults who were hospitalized with CAP in Oxfordshire, England, from January 1, 2016 through March, 19, 2024, and received initial treatment with amoxicillin or co-amoxiclav, researchers from the University of Oxford examined the effect of adjunctive macrolides on 30-day all-cause mortality, time to hospital discharge, and changes in Sequential Organ Failure Assessment (SOFA) score. While guidelines from the British Thoracic Society and the National Institute for…